Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of SCTV01E in Vaccinated Population
NCT05652543Phase 2Completed
- Sponsor
- Sinocelltech Group Limited
- Start
- Jan 2023
- Primary completion
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SCTV01E in coronavirus disease 2019 (COVID-19), sponsored by Sinocelltech Group Limited. Started Jan 2023; status: completed.
02
Drugs
SCTV01E
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05652543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05652543.